<DOC>
	<DOC>NCT00849550</DOC>
	<brief_summary>The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.</brief_summary>
	<brief_title>Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Must be 18 years or older Must have a performance status of at least 70% (able to carry on most normal activities) Must have life expectancy of at least 3 months Must have adequate organ and marrow function as determined by lab tests Women of childbearing potential and men must agree to use two forms of contraception Ability and willingness to sign a written informed consent document Histologically confirmed solid tumor malignancy that is metastatic or unresectable Pregnant or breastfeeding and/or lactating women Patients who have received any other investigational agents within 28 days of the first day of study drug Patients with known CNS metastases History of other carcinomas within last 5 years (except nonmelanoma skin cancer, insitu cervical cancer, localized prostate cancer) Inadequately controlled hypertension Significant vascular disease Invasion or encasement of a major artery Evidence of bleeding diathesis or coagulopathy Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 of study drug Serious illness or medical condition History of myocardial infarction, unstable angina, cardiac or other vascular stenting History of stroke HIV, Hepatitis C, Hepatitis B or other serious chronic infection Impairment of Gastrointestinal function or disease History of interstitial lung disease Patients who have had radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within 28 days of receiving study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>XELOX</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>RAD001</keyword>
</DOC>